| BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders |
Regulatory Approvals In-Process; New Record Date to be Set Shortly
“BioTime remains committed to distributing AgeX shares to Details on the AgeX Distribution
A new record date for the distribution of AgeX shares owned by
For more detail on AgeX’s business, risk factors, and uncertainties, shareholders should carefully review the AgeX Information Statement filed as an exhibit to its Registration Statement on Form 10 filed with the SEC at www.sec.gov. Copies of a definitive Information Statement relating to the distribution will be mailed to all BioTime shareholders entitled to receive AgeX common stock in the distribution. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About
BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is producing new cells and tissues with
its proprietary pluripotent cell technologies. These cells and tissues
are developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases or injuries. BioTime’s cell/drug
delivery programs are based upon its proprietary HyStem® cell
and drug delivery hydrogel matrix technology. HyStem® was
designed, in part, to provide for the transfer, retention and/or
engraftment of cellular replacement therapies. HyStem® is a
unique hydrogel that has been shown to support cellular attachment and
proliferation in vivo. Current research at leading medical institutions
has shown that HyStem® is compatible with a wide variety of
cells and tissue types including brain, bone, skin, cartilage, vascular
and heart tissues. Due to the unique cross-linking chemistry, HyStem® hydrogels
have the ability to mix cells, biologics and small molecule drugs and
can be injected or applied as a gel which allows the hydrogel to conform
to a cavity or space. This property of HyStem® hydrogels
offers several distinct advantages over other hydrogels, including the
possibility of combining bioactive materials with the hydrogel at the
point of use. BioTime is also developing HyStem® for
the delivery of therapeutic drugs and cells to localized areas of the
body, including for sustained drug release in the targeted anatomical
sites. BioTime’s lead cell delivery clinical program is Renevia®,
which consists of HyStem® combined with the patient's
own adipose (fat) derived tissue or cells. Renevia® met its
primary endpoint in an EU pivotal clinical trial for the treatment of
facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia® for
CE Mark approval in the EU. There were no device related serious adverse
events reported to date. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium
transplant therapy, which is in a Phase I/IIa multicenter clinical trial
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. There have been no unexpected
serious adverse events reported to date. BioTime also has significant
equity holdings in two publicly traded companies,
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com. About AgeX Therapeutics
For more information, please visit www.agexinc.com or
connect with the company on Twitter, Forward-Looking Statements
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Investors are
cautioned that statements in this press release regarding: (a) any value
to BioTime shareholders of the remaining AgeX common stock or the
promissory note from Juvenescence and the potential for liquidity of
those assets; (b) BioTime's plans or expectations for distribution of
AgeX common stock to
View source version on businesswire.com: https://www.businesswire.com/news/home/20180916005041/en/ Source:
BioTime Investor and Media Contact: |
Menu